Development of two-dimensional template system for the prediction of CYP2B6-mediated reaction sites

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 4, 2011, Pages 309-330

  Koyama, Noriyuki ^a,b   Yamazoe, Yasushi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

CYP2B6; Planar templates; Predicting system; Regioselectivity; Stereoselectivity; Substrate specificity; Substrate based approach

Indexed keywords

CYTOCHROME P450 2B6; POLYCYCLIC AROMATIC HYDROCARBON;

ACCURACY; ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; IN VITRO STUDY; METABOLIC REGULATION; PREDICTION; PROCESS DEVELOPMENT; RACEMIZATION; REACTION TIME; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THREE DIMENSIONAL IMAGING; VALIDATION PROCESS;

EID: 80052572983     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-RG-097     Document Type: Article

References (106)

1. Wang, H. and Tompkins, L. M.: CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr. Drug Metab., 9: 598-610 (2008).
2. Hodgson, E. and Rose, R. L.: The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals. Pharmacol. Ther., 113: 420-428 (2007).
3. Ekins, S., Bravi, G., Ring, B. J., Gillespie, T. A., Gillespie, J. S., Vandenbranden, M., Wrighton, S. A. and Wikel, J. H.: Threedimensional quantitative structure activity relationship analyses of substrates for CYP2B6. J. Pharmacol. Exp. Ther., 288: 21-29 (1999).
4. Ekins, S., Iyer, M., Krasowski, M. D. and Kharasch, E. D.: Molecular characterization of CYP2B6 substrates. Curr. Drug Metab., 9: 363-373 (2008).
5. Wang, Q. and Halpert, J. R.: Combined three-dimensional quantitative structure-activity relationship analysis of cytochrome P450 2B6 substrates and protein homology modeling. Drug Metab. Dispos., 30: 86-95 (2002).
6. Shou, M., Korzekwa, K. R., Crespi, C. L., Gonzalez, F. J. and Gelboin, H. V.: The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol. Mol. Carcinog., 10: 159-168 (1994).
7. Shou, M., Krausz, K. W., Gonzalez, F. J. and Gelboin, H. V.: Metabolic activation of the potent carcinogen dibenzo[a,l]pyrene by human recombinant cytochromes P450, lung and liver microsomes. Carcinogenesis, 17: 2429-2433 (1996).
8. Shou, M., Krausz, K. W., Gonzalez, F. J. and Gelboin, H. V.: Metabolic activation of the potent carcinogen dibenzo[a,h]anthracene by cDNA-expressed human cytochromes P450. Arch. Biochem. Biophys., 328: 201-207 (1996).
9. Nakajima, T., Wang, R. S., Elovaara, E., Gonzalez, F. J., Gelboin, H. V., Raunio, H., Pelkonen, O., Vainio, H. and Aoyama, T.: Toluene metabolism by cDNA-expressed human hepatic cytochrome P450. Biochem. Pharmacol., 53: 271-277 (1997).
10. Kim, H., Wang, R. S., Elovaara, E., Raunio, H., Pelkonen, O., Aoyama, T., Vainio, H. and Nakajima, T.: Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica, 27: 657-665 (1997).
11. Sams, C., Loizou, G. D., Cocker, J. and Lennard, M. S.: Metabolism of ethylbenzene by human liver microsomes and recombinant human cytochrome P450s (CYP). Toxicol. Lett., 147: 253-260 (2004).
12. Cho, T. M., Rose, R. L. and Hodgson, E.: In vitro metabolism of naphthalene by human liver microsomal cytochrome P450 enzymes. Drug Metab. Dispos., 34: 176-183 (2006).
13. Shou, M., Korzekwa, K. R., Krausz, K. W., Crespi, C. L., Gonzalez, F. J. and Gelboin, H. V.: Regio- and stereo-selective metabolism of phenanthrene by twelve cDNA-expressed human, rodent, and rabbit cytochromes P-450. Cancer Lett., 83: 305-313 (1994).
14. Zhuo, X., Gu, J., Zhang, Q. Y., Spink, D. C., Kaminsky, L. S. and Ding, X.: Biotransformation of coumarin by rodent and human cytochromes P-450: metabolic basis of tissue-selective toxicity in olfactory mucosa of rats and mice. J. Pharmacol. Exp. Ther., 288: 463-471 (1999).
15. Marini, S., Grasso, E., Longo, V., Puccini, P., Riccardi, B. and Gervasi, P. G.: 4-Biphenylaldehyde and 9-anthraldehyde: two fluorescent substrates for determining P450 enzyme activities in rat and human. Xenobiotica, 33: 1-11 (2003).
16. Shou, M., Korzekwa, K. R., Krausz, K. W., Buters, J. T., Grogan, J., Goldfarb, I., Hardwick, J. P., Gonzalez, F. J. and Gelboin, H. V.: Specificity of cDNA-expressed human and rodent cytochrome P450s in the oxidative metabolism of the potent carcinogen 7,12-dimethylbenzaa]anthracene. Mol. Carcinog., 17: 241-249 (1996).
17. Wójcikowski, J., Pichard-Garcia, L., Maurel, P. and Daniel, W. A.: Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br. J. Pharmacol., 138: 1465-1474 (2003).
18. Wójcikowski, J., Pichard-Garcia, L., Maurel, P. and Daniel, W. A.: The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur. Neuropsychopharmacol., 14: 199-208 (2004).
19. Yamazaki, H., Inoue, K., Mimura, M., Oda, Y., Guengerich, F. P. and Shimada, T.: 7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Biochem. Pharmacol., 51: 313-319 (1996).
20. Code, E. L., Crespi, C. L., Penman, B. W., Gonzalez, F. J., Chang, T. K. and Waxman, D. J.: Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos., 25: 985-993 (1997).
21. Renwick, A. B., Surry, D., Price, R. J., Lake, B. G. and Evans, D. C.: Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms. Xenobiotica, 30: 955-969 (2000).
22. Erickson, D. A., Mather, G., Trager, W. F., Levy, R. H. and Keirns, J. J.: Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab. Dispos., 27: 1488-1495 (1999).
23. Davies, B. J., Coller, J. K., Somogyi, A. A., Milne, R. W. and Sallustio, B. C.: CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab. Dispos., 35: 128-138 (2007).
24. Ward, B. A., Gorski, J. C., Jones, D. R., Hall, S. D., Flockhart, D. A. and Desta, Z.: The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther., 306: 287-300 (2003).
25. Ono, S., Hatanaka, T., Miyazawa, S., Tsutsui, M., Aoyama, T., Gonzalez, F. J. and Satoh, T.: Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica, 26: 1155-1166 (1996).
26. Giraud, C., Tran, A., Rey, E., Vincent, J., Treluyer, J. M. and Pons, G.: In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab. Dispos., 32: 1279-1286 (2004).
27. Koyama, E., Chiba, K., Tani, M. and Ishizaki, T.: Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J. Pharmacol. Exp. Ther., 278: 21-30 (1996).
28. Imaoka, S., Yamada, T., Hiroi, T., Hayashi, K., Sakaki, T., Yabusaki, Y. and Funae, Y.: Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem. Pharmacol., 51: 1041-1050 (1996).
29. Domanski, T. L., Schultz, K. M., Roussel, F., Stevens, J. C. and Halpert, J. R.: Structure-function analysis of human cytochrome P-450 2B6 using a novel substrate, site-directed mutagenesis, and molecular modeling. J. Pharmacol. Exp. Ther., 290: 1141-1147 (1999).
30. Shou, M., Korzekwa, K. R., Brooks, E. N., Krausz, K. W., Gonzalez, F. J. and Gelboin, H. V.: Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis, 18: 207-214 (1997).
31. Kent, U. M., Mills, D. E., Rajnarayanan, R. V., Alworth, W. L. and Hollenberg, P. F.: Effect of 17-alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J. Pharmacol. Exp. Ther., 300: 549-558 (2002).
32. Gay, S. C., Shah, M. B., Talakad, J. C., Maekawa, K., Roberts, A. G., Wilderman, P. R., Sun, L., Yang, J. Y., Huelga, S. C., Hong, W. X., Zhang, Q., Stout, C. D. and Halpert, J. R.: Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution. Mol. Pharmacol., 77: 529-538 (2010).
33. Scott, E. E., White, M. A., He, Y. A., Johnson, E. F., Stout, C. D. and Halpert, J. R.: Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl)imidazole at 1.9-A resolution: insight into the range of P450 conformations and the coordination of redox partner binding. J. Biol. Chem., 279: 27294-27301 (2004).
34. Neff, J. A. and Moody, D. E.: Differential N-demethylation of l-alpha-acetylmethadol (LAAM) and norLAAM by cytochrome P450s 2B6, 2C18, and 3A4. Biochem. Biophys. Res. Commun., 284: 751-756 (2001).
35. Ekins, S., Vandenbranden, M., Ring, B. J., Gillespie, J. S., Yang, T. J., Gelboin, H. V. and Wrighton, S. A.: Further characterization of the expression in liver and catalytic activity of CYP2B6. J. Pharmacol. Exp. Ther., 286: 1253-1259 (1998).
36. Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I. and Greenblatt, D. J.: CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos., 28: 1176-1183 (2000).
37. Coles, R. and Kharasch, E. D.: Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes. Pharm. Res., 25: 1405-1411 (2008).
38. Kraemer, T., Pflugmann, T., Bossmann, M., Kneller, N. M., Peters, F. T., Paul, L. D., Springer, D., Staack, R. F. and Maurer, H. H.: Fenproporex N-dealkylation to amphetamine- enantioselective in vitro studies in human liver microsomes as well as enantioselective in vivo studies in Wistar and Dark Agouti rats. Biochem. Pharmacol., 68: 947-957 (2004).
39. Margolis, J. M., OöDonnell, J. P., Mankowski, D. C., Ekins, S. and Obach, R. S.: (R)-, (S)-, and racemic fluoxetine Ndemethylation by human cytochrome P450 enzymes. Drug Metab. Dispos., 28: 1187-1191 (2000).
40. Kim, K. A., Chung, J., Jung, D. H. and Park, J. Y.: Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur. J. Clin. Pharmacol., 60: 575-581 (2004).
41. Ramírez, J., Innocenti, F., Schuetz, E. G., Flockhart, D. A., Relling, M. V., Santucci, R. and Ratain, M. J.: CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro Ndemethylation of meperidine in human liver microsomes. Drug Metab. Dispos., 32: 930-936 (2004).
42. Gerber, J. G., Rhodes, R. J. and Gal, J.: Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality, 16: 36-44 (2004).
43. Labbé, L., Abolfathi, Z., Lessard, E., Pakdel, H., Beaune, P. and Turgeon, J.: Role of specific cytochrome P450 enzymes in the N-oxidation of the antiarrhythmic agent mexiletine. Xenobiotica, 33: 13-25 (2003).
44. Stevens, J. C., White, R. B., Hsu, S. H. and Martinet, M.: Human liver CYP2B6-catalyzed hydroxylation of RP 73401. J. Pharmacol. Exp. Ther., 282: 1389-1395 (1997).
45. Hidestrand, M., Oscarson, M., Salonen, J. S., Nyman, L., Pelkonen, O., Turpeinen, M. and Ingelman-Sundberg, M.: CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinsonös disease, as revealed from experiments with recombinant enzymes. Drug Metab. Dispos., 29: 1480-1484 (2001).
46. Salonen, J. S., Nyman, L., Boobis, A. R., Edwards, R. J., Watts, P., Lake, B. G., Price, R. J., Renwick, A. B., Gomez-Lechon, M. J., Castell, J. V., Ingelman-Sundberg, M., Hidestrand, M., Guillouzo, A., Corcos, L., Goldfarb, P. S., Lewis, D. F., Taavitsainen, P. and Pelkonen, O.: Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab. Dispos., 31: 1093-1102 (2003).
47. Bae, S. K., Cao, S., Seo, K. A., Kim, H., Kim, M. J., Shon, J. H., Liu, K. H., Zhou, H. H. and Shin, J. G.: Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-m1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyln- N,N-dimethylamine) metabolites in human liver microsomes. Drug Metab. Dispos., 36: 1679-1688 (2008).
48. Kobayashi, K., Abe, S., Nakajima, M., Shimada, N., Tani, M., Chiba, K. and Yamamoto, T.: Role of human CYP2B6 in S-mephobarbital N-demethylation. Drug Metab. Dispos., 27: 1429-1433 (1999).
49. Waxman, D. J., Lapenson, D. P., Aoyama, T., Gelboin, H. V., Gonzalez, F. J. and Korzekwa, K.: Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch. Biochem. Biophys., 290: 160-166 (1991).
50. Gervot, L., Rochat, B., Gautier, J. C., Bohnenstengel, F., Kroemer, H., de Berardinis, V., Martin, H., Beaune, P. and de Waziers, I.: Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics, 9: 295-306 (1999).
51. Hanna, I. H., Reed, J. R., Guengerich, F. P. and Hollenberg, P. F.: Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. Arch. Biochem. Biophys., 376: 206-216 (2000).
52. Usmani, K. A., Rose, R. L., Goldstein, J. A., Taylor, W. G., Brimfield, A. A. and Hodgson, E.: In vitro human metabolism and interactions of repellent N,N-diethyl-m-toluamide. Drug Metab. Dispos., 30: 289-294 (2002).
53. Tang, J., Cao, Y., Rose, R. L., Brimfield, A. A., Dai, D., Goldstein, J. A. and Hodgson, E.: Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes. Drug Metab. Dispos., 29: 1201-1204 (2001).
54. Buratti, F. M., Volpe, M. T., Meneguz, A., Vittozzi, L. and Testai, E.: CYP-specific bioactivation of four organophosphorothioate pesticides by human liver microsomes. Toxicol. Appl. Pharmacol., 186: 143-154 (2003).
55. Mutch, E. and Williams, F. M.: Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology, 224: 22-32 (2006).
56. Foxenberg, R. J., McGarrigle, B. P., Knaak, J. B., Kostyniak, P. J. and Olson, J. R.: Human hepatic cytochrome p450-specific metabolism of parathion and chlorpyrifos. Drug Metab. Dispos., 35: 189-193 (2007).
57. Kappers, W. A., Edwards, R. J., Murray, S. and Boobis, A. R.: Diazinon is activated by CYP2C19 in human liver. Toxicol. Appl. Pharmacol., 177: 68-76 (2001).
58. Buratti, F. M., DöAniello, A., Volpe, M. T., Meneguz, A. and Testai, E.: Malathion bioactivation in the human liver: the contribution of different cytochrome p450 isoforms. Drug Metab. Dispos., 33: 295-302 (2005).
59. Usmani, K. A., Karoly, E. D., Hodgson, E. and Rose, R. L.: In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily. Drug Metab. Dispos., 32: 333-339 (2004).
60. Hu, Y. and Kupfer, D.: Metabolism of the endocrine disruptor pesticide-methoxychlor by human P450s: pathways involving a novel catechol metabolite. Drug Metab. Dispos., 30: 1035-1042 (2002).
61. Lang, D. H., Rettie, A. E. and Bocker, R. H.: Identification of enzymes involved in the metabolism of atrazine, terbuthylazine, ametryne, and terbutryne in human liver microsomes. Chem. Res. Toxicol., 10: 1037-1044 (1997).
62. Tang, J., Cao, Y., Rose, R. L. and Hodgson, E.: In vitro metabolism of carbaryl by human cytochrome P450 and its inhibition by chlorpyrifos. Chem. Biol. Interact., 141: 229-241 (2002).
63. Heyn, H., White, R. B. and Stevens, J. C.: Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab. Dispos., 24: 948-954 (1996).
64. Ko, J. W., Desta, Z. and Flockhart, D. A.: Human Ndemethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. Drug Metab. Dispos., 26: 775-778 (1998).
65. Bort, R., Mace, K., Boobis, A., Gomez-Lechon, M. J., Pfeifer, A. and Castell, J.: Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem. Pharmacol., 58: 787-796 (1999).
66. Kiang, T. K., Ho, P. C., Anari, M. R., Tong, V., Abbott, F. S. and Chang, T. K.: Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol. Sci., 94: 261-271 (2006).
67. Tsuji, R., Isobe, N., Kurita, Y., Hanai, K., Yabusaki, Y. and Kawasaki, H.: Species difference in the inhibition of pentobarbital metabolism by empenthrin. Environ. Toxicol. Pharmacol., 2: 331-337 (1996).
68. Hesse, L. M., Venkatakrishnan, K., von Moltke, L. L., Shader, R. I. and Greenblatt, D. J.: CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab. Dispos., 29: 133-140 (2001).
69. Cameron, M. D., Wright, J., Black, C. B. and Ye, N.: In vitro prediction and in vivo verification of enantioselective human tofisopam metabolite profiles. Drug Metab. Dispos., 35: 1894-1902 (2007).
70. Yanagihara, Y., Kariya, S., Ohtani, M., Uchino, K., Aoyama, T., Yamamura, Y. and Iga, T.: Involvement of CYP2B6 in ndemethylation of ketamine in human liver microsomes. Drug Metab. Dispos., 29: 887-890 (2001).
71. Hijazi, Y. and Boulieu, R.: Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab. Dispos., 30: 853-858 (2002).
72. Tougou, K., Gotou, H., Ohno, Y. and Nakamura, A.: Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica, 34: 449-461 (2004).
73. Yu, J., Brown, D. G. and Burdette, D.: In vitro metabolism studies of nomifensine monooxygenation pathways: metabolite identification, reaction phenotyping, and bioactivation mechanism. Drug Metab. Dispos., 38: 1767-1778 (2010).
74. Grace, J. M., Aguilar, A. J., Trotman, K. M., Peggins, J. O. and Brewer, T. G.: Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450. Drug Metab. Dispos., 26: 313-317 (1998).
75. Zhao, X. J., Yokoyama, H., Chiba, K., Wanwimolruk, S. and Ishizaki, T.: Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. J. Pharmacol. Exp. Ther., 279: 1327-1334 (1996).
76. Pearce, R. E., Vakkalagadda, G. R. and Leeder, J. S.: Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3- hydroxylated metabolites. Drug Metab. Dispos., 30: 1170-1179 (2002).
77. Pearce, R. E., Lu, W., Wang, Y., Uetrecht, J. P., Correia, M. A. and Leeder, J. S.: Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug Metab. Dispos., 36: 1637-1649 (2008).
78. Shiraga, T., Kaneko, H., Iwasaki, K., Tozuka, Z., Suzuki, A. and Hata, T.: Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica, 29: 217-229 (1999).
79. Chou, Y. C., Chung, Y. T., Liu, T. Y., Wang, S. Y., Chau, G. Y., Chi, C. W., Soucek, P., Krausz, K. W., Gelboin, H. V., Lee, C. H. and Ueng, Y. F.: The oxidative metabolism of dimemorfan by human cytochrome P450 enzymes. J. Pharm. Sci., 99: 1063-1077 (2010).
80. Obach, R. S., Cox, L. M. and Tremaine, L. M.: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab. Dispos., 33: 262-270 (2005).
81. Hagihara, K., Nishiya, Y., Kurihara, A., Kazui, M., Farid, N. A. and Ikeda, T.: Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab. Pharmacokinet., 23: 412-420 (2008).
82. Kazui, M., Nishiya, Y., Ishizuka, T., Hagihara, K., Farid, N. A., Okazaki, O., Ikeda, T. and Kurihara, A.: Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos., 38: 92-99 (2010).
83. Desta, Z., Ward, B. A., Soukhova, N. V. and Flockhart, D. A.: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther., 310: 1062-1075 (2004).
84. Notley, L. M., Crewe, K. H., Taylor, P. J., Lennard, M. S. and Gillam, E. M.: Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its alpha-hydroxy and alpha,4-dihydroxy derivatives. Chem. Res. Toxicol., 18: 1611-1618 (2005).
85. Crewe, H. K., Notley, L. M., Wunsch, R. M., Lennard, M. S. and Gillam, E. M.: Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4$-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos., 30: 869-874 (2002).
86. Yamazaki, H., Inoue, K., Hashimoto, M. and Shimada, T.: Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch. Toxicol., 73: 65-70 (1999).
87. Yamanaka, H., Nakajima, M., Fukami, T., Sakai, H., Nakamura, A., Katoh, M., Takamiya, M., Aoki, Y. and Yokoi, T.: CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab. Dispos., 33: 1811-1818 (2005).
88. Subrahmanyam, V., Renwick, A. B., Walters, D. G., Young, P. J., Price, R. J., Tonelli, A. P. and Lake, B. G.: Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab. Dispos., 29: 1146-1155 (2001).
89. Desta, Z., Soukhova, N., Mahal, S. K. and Flockhart, D. A.: Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab. Dispos., 28: 789-800 (2000).
90. Goda, R., Nagai, D., Akiyama, Y., Nishikawa, K., Ikemoto, I., Aizawa, Y., Nagata, K. and Yamazoe, Y.: Detection of a new Noxidized metabolite of flutamide, N-a4-nitro-3-(trifluoromethyl)- phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients. Drug Metab. Dispos., 34: 828-835 (2006).
91. Yoshii, K., Kobayashi, K., Tsumuji, M., Tani, M., Shimada, N. and Chiba, K.: Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci., 67: 175-184 (2000).
92. Wójcikowski, J., Boksa, J. and Daniel, W. A.: Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to Ndemethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver-A comparison with other phenothiazines. Biochem. Pharmacol., 80: 1252-1259 (2010).
93. Lee, H. S., Park, E. J., Ji, H. Y., Kim, S. Y., Im, G. J., Lee, S. M. and Jang, I. J.: Identification of cytochrome P450 enzymes responsible for N-dealkylation of a new oral erectogenic, mirodenafil. Xenobiotica, 38: 21-33 (2008).
94. Kumar, G. N., Dubberke, E., Rodrigues, A. D., Roberts, E. and Dennisen, J. F.: Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab. Dispos., 25: 110-115 (1997).
95. Chiba, M., Xu, X., Nishime, J. A., Balani, S. K. and Lin, J. H.: Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab. Dispos., 25: 1022-1031 (1997).
96. Yoneda, K., Matsumoto, I., Sutoh, F., Higashi, R., Nunoya, K., Nakade, S., Miyata, Y. and Ogawa, M.: In vitro metabolism and inhibitory effects of pranlukast in human liver microsomes. Biol. Pharm. Bull., 32: 688-693 (2009).
97. Evans, D. C., OöConnor, D., Lake, B. G., Evers, R., Allen, C. and Hargreaves, R.: Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab. Dispos., 31: 861-869 (2003).
98. Kobayashi, K., Chiba, K., Yagi, T., Shimada, N., Taniguchi, T., Horie, T., Tani, M., Yamamoto, T., Ishizaki, T. and Kuroiwa, Y.: Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J. Pharmacol. Exp. Ther., 280: 927-933 (1997).
99. Stiborová, M., Sejbal, J., Borek-Dohalská, L., Aimová, D., Poljaková, J., Forsterová, K., Rupertová, M., Wiesner, J., Hudecek, J., Wiessler, M. and Frei, E.: The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res., 64: 8374-8380 (2004).
100. Usmani, K. A., Hodgson, E. and Rose, R. L.: In vitro metabolism of carbofuran by human, mouse, and rat cytochrome P450 and interactions with chlorpyrifos, testosterone, and estradiol. Chem. Biol. Interact., 150: 221-232 (2004).
101. Miyazawa, M., Sugie, A. and Shimada, T.: Roles of human CYP2A6 and 2B6 and rat CYP2C11 and 2B1 in the 10- hydroxylation of (%)-verbenone by liver microsomes. Drug Metab. Dispos., 31: 1049-1053 (2003).
102. Miyazawa, M. and Gyoubu, K.: Metabolism of (%)-fenchone by CYP2A6 and CYP2B6 in human liver microsomes. Xenobiotica, 37: 194-204 (2007).
103. Miyazawa, M., Shindo, M. and Shimada, T.: Roles of cytochrome P450 3A enzymes in the 2-hydroxylation of 1,4-cineole, a monoterpene cyclic ether, by rat and human liver microsomes. Xenobiotica, 31: 713-723 (2001).
104. Miyazawa, M., Shindo, M. and Shimada, T.: Oxidation of 1,8- cineole, the monoterpene cyclic ether originated from Eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes. Drug Metab. Dispos., 29: 200-205 (2001).
105. Miller, K. K., Cai, J., Ripp, S. L., Pierce, W. M., Jr., Rushmore, T. H. and Prough, R. A.: Stereo- and regioselectivity account for the diversity of dehydroepiandrosterone (DHEA) metabolites produced by liver microsomal cytochromes P450. Drug Metab. Dispos., 32: 305-313 (2004).
106. Miksanová, M., Sulc, M., Rýdlová, H., Schmeiser, H. H., Frei, E. and Stiborová, M.: Enzymes involved in the metabolism of the carcinogen 2-nitroanisole: evidence for its oxidative detoxication by human cytochromes P450. Chem. Res. Toxicol., 17: 663-671 (2004).